Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
This 21st-century centre of cutting-edge science is also a medieval site of celestial auguries, of miracle cures performed and witnessed ...
Appetite is governed by gut hormones, not willpower. GLP-1 therapies extend natural satiety signals and expose the biology behind eating.
Sogroya® (somapacitan-beco) is a once-weekly treatment option, offering an alternative to once-daily therapy, which may help ...
The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...
Zepbound KwikPen, a 4-dose single-patient delivery device for tirzepatide administration has been made available by Lilly.
FDA approves swallowable Allurion Gastric Balloon for weight loss in adults with obesity who failed prior lifestyle programs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results